Oral Antidiabetic Drugs and GLP-1 Analogues in the Treatment of Type 2 Diabetes - Related Resources

Cochrane reviews

• Glucagon-like peptide analogues (exanatide orliraglutide), in combination with metformin or sulphonylurea or both, are effective in improving glycaemic control in patients with type 2 diabetes. Glucagon-Like Peptide Analogues (GLP-1 Analogues) for Type 2 Diabetes
• Rosiglitazone is not effective in improving patient-oriented outcomes such as mortality, morbidity, costs and health-related quality of life for type 2 diabetes mellitus. It appears to increase the occurrence of oedema and the risk of myocardial infarction Rosiglitazone for Type 2 Diabetes Mellitus.
• The use of DPP-4 inhibitors appears to result in a slight improvement in glycaemic control compared to placebo, but there are no data on patient-oriended outcomes such as health-related quality of life, diabetic complications and all-cause mortality, and there is insufficient evidence on the effectiveness of DPP-4 inhibitors as add-on drugs Dipeptidyl Peptidase-4 (Dpp-4) Inhibitors for Type 2 Diabetes Mellitus.

Other evidence summaries

• Metformin lowers blood glucose as effectively as sulfonylureas, with the advantage of better weight control Metformin in the Treatment of Type II Diabetes.
• Acarbose may be a reasonable choice as adjunct therapy for patients with poorly controlled NIDDM Acarbose in the Treatment of Diabetes Mellitus.
• Incretin-based therapy with GLP-1 analogues or DPP4 inhibitors in adults with type 2 diabetes is moderately effective in improving glycaemic control, with greater reductions in postprandial glycaemia and favourable (GLP-1 analogues) or neutral (DPP4 inhibitors) effects on weight. Long-term efficacy and safety are under surveillance Incretin-Based Therapy with Dipeptidyl Peptidase 4 Inhibitors in Type 2 Diabetes.

Literature